PMID- 2104787
OWN - NLM
STAT- MEDLINE
DCOM- 19900222
LR  - 20190820
IS  - 0090-1229 (Print)
IS  - 0090-1229 (Linking)
VI  - 54
IP  - 2
DP  - 1990 Feb
TI  - Peripheral blood monocytes derived from HIV+ individuals mediate 
      antibody-dependent cellular cytotoxicity (ADCC).
PG  - 192-9
AB  - Monocytes/macrophages serve a number of immunologic functions and play a major 
      role in the host defense against infection. Abnormal functions of monocytes have 
      been reported in AIDS and HIV+ individuals. A recent report from our laboratory 
      demonstrated that peripheral blood monocytes (PBM) derived from AIDS patients 
      were de novo "activated" as assessed by direct cell-mediated cytotoxicity (CMC) 
      and secretion of cytotoxic factors and tumor necrosis factor-alpha (TNF alpha). 
      Thus, both the direct cytotoxicity as well as the antibody-dependent cellular 
      cytotoxicity (ADCC) exerted by the monocytes may contribute to the destruction of 
      HIV-infected/coated cells and the immunopathogenesis of AIDS. The present study 
      investigated the ability of HIV+ PBM to mediate ADCC against antibody-coated 
      target cells in an 18-hr 51Cr release assay. Initial studies examined ADCC using 
      a macrophage resistant target Raji and rabbit anti-Raji serum. The results show 
      that the majority of PBM from HIV+ individuals mediate ADCC activity while the 
      majority of PBM from normal healthy controls was not cytotoxic. While activation 
      of PBM with recombinant interferon-gamma (rIFN-gamma) enhances the ADCC activity 
      of normal PBM, treatment of HIV+ PBM with IFN-gamma resulted in significant 
      enhancement of ADCC. Both untreated and treated PBM from HIV+ individuals had 
      significantly higher ADCC than PBM from normal individuals. Of interest, a 
      significant ADCC activity was found by PBM derived from two HIV- high risk 
      individuals whether untreated or treated with rIFN-gamma. The ADCC results with 
      RAJI target cells prompted us to investigate whether ADCC can also be obtained 
      using HIV-infected T4+ cells. We selected a macrophage and TNF resistant T4+ CEM 
      cell line as target for ADCC. The target was coated with inactivated HIV and 
      pooled human anti-HIV serum was used. Studies with a few HIV+ individuals 
      demonstrate that significant ADCC is obtained with PBM from HIV+ individuals but 
      little or no ADCC by normal PBM and the ADCC was specific for HIV. The ADCC was 
      also significantly enhanced by treatment of PBM with rIFN-gamma. The results of 
      this study clearly indicate that PBM from HIV+ individuals are endowed with the 
      capacity to mediate ADCC against HIV-infected/coated cells and thus, we postulate 
      that PBM may play a direct role in vivo in lysis or suppression of 
      HIV-coated/infected cells and in the pathogenesis of AIDS.
FAU - Jewett, A
AU  - Jewett A
AD  - Department of Microbiology and Immunology, UCLA School of Medicine.
FAU - Bonavida, B
AU  - Bonavida B
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Clin Immunol Immunopathol
JT  - Clinical immunology and immunopathology
JID - 0356637
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 82115-62-6 (Interferon-gamma)
SB  - IM
MH  - Antibody-Dependent Cell Cytotoxicity/*immunology
MH  - Cells, Cultured
MH  - HIV/immunology
MH  - HIV Infections/*immunology
MH  - Humans
MH  - *Immunity, Cellular
MH  - In Vitro Techniques
MH  - Interferon-gamma/pharmacology
MH  - Monocytes/*immunology
MH  - Tumor Necrosis Factor-alpha/metabolism
EDAT- 1990/02/01 00:00
MHDA- 1990/02/01 00:01
CRDT- 1990/02/01 00:00
PHST- 1990/02/01 00:00 [pubmed]
PHST- 1990/02/01 00:01 [medline]
PHST- 1990/02/01 00:00 [entrez]
AID - 10.1016/0090-1229(90)90081-z [doi]
PST - ppublish
SO  - Clin Immunol Immunopathol. 1990 Feb;54(2):192-9. doi: 
      10.1016/0090-1229(90)90081-z.